Pharma giant Roche sees income soar in first half
Net income jumped 17 percent to reach 7.8 billion Swiss francs ($9.85 billion), while the Basel-based group confirmed its full-year outlook.
Its sales exceeded forecasts, rising four percent to 30.9 billion Swiss francs -- or a seven-percent hike excluding currency effects, the world leader in cancer treatments said in a statement.
Roche has two branches: pharmaceuticals and diagnostics.
Its pharmaceuticals division saw sales rise 10 percent, at constant exchange rates, to 24 billion francs, primarily thanks to five "growth driver" medicines, including for breast cancer and asthma, which achieved total sales of 10.6 billion francs.
That was 1.7 billion more than during the first half of 2024.
Sales in its diagnostics division, however, were flat at constant exchange rates, at 6.95 billion francs.
"We received numerous important approvals and reported positive data in disease areas with high unmet medical need," said Roche chief executive Thomas Schinecker.
"Over the past six months, we have made significant progress in our pipeline and advanced four potentially practice-changing therapies into the final phase of clinical development," he said.
These are NXT007 in haemophilia A, trontinemab in Alzheimer's disease, prasinezumab in early-stage Parkinson's disease, and zosurabalpin, "a novel antibiotic that could become the first in over 50 years to tackle a type of bacteria that has become resistant to most other treatments".
For the full year, Roche said it was still targeting mid-single-digit sales growth excluding currency effects, equivalent to around five percent growth.
In April, Roche announced plans to invest $50 billion in the United States over the next five years, following in the footsteps of Swiss rival Novartis, with US President Donald Trump's tariff war fuelling uncertainty in the sector.
The United States is a key market for the pharmaceutical industry, representing around half of sales in Roche's pharmaceutical division.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
2 days ago
- France 24
Golf course and trade talks: Donald Trump mixes business & politics in Scotland
00:52 25/07/2025 Zelensky seeks EU support while Ukraine struggles with corruption Europe 24/07/2025 EU-China ties hit 'inflection point' and calls climate chage 'a priority' Europe 24/07/2025 EU says China's links with Russia now 'determining factor' in ties Europe 24/07/2025 EU tariffs on chinese EVs strain trade and diplomatic ties with Beijing Economy 24/07/2025 Spain beats Germany in Women's Euro 2025 and will play England on Sunday Europe 24/07/2025 War in Ukraine : Russia agrees prisoner swap but no deal on ceaserfire Europe 20/07/2025 Zelensky offers to hold new talks for ceasefire Europe 19/07/2025 EU launches new sanctions against Russia for more effective oil price cap Europe 17/07/2025 EU proposes 'most ambitious ever' budget of two trillion euros Europe
Euronews
2 days ago
- Euronews
EU regulator backs new Alzheimer's drug, months after rejecting it
The European Union's medicines regulator is reversing course on its decision to block a new Alzheimer's disease treatment, saying the drug can be offered to certain patients under strict safety protocols. In late March, the European Medicines Agency's (EMA) drug evaluators said the risks did not outweigh the benefits for the medicine donanemab, which can slow the progression of early-stage Alzheimer's but also raises the risk of potentially deadly brain swelling and bleeding. But in a revised opinion on Friday, the group said donanemab can be offered to a specific subset of Alzheimer's patients in tightly controlled settings. Donanemab, which is sold by Eli Lilly as Kisunla, is a monoclonal antibody taken via a once-monthly infusion. It's already been approved in the United Kingdom, the United States, Japan, and China. In a clinical trial, Kisunla slowed dementia symptoms by up to 35 per cent over 18 months – but three people died with serious amyloid‑related imaging abnormalities (ARIA), which are a common side effect of the medicine that can cause swelling and bleeding in the brain. Two of these patients carried a type of gene that raises the risk of Alzheimer's, and Lilly had suggested that the medicine only be offered to people who do not have the gene. In March, the EMA committee said that people without the gene were still at risk of fatal complications from ARIA. On Friday, the group said the drug can be offered to early Alzheimer's patients who have at most one copy of the gene – but only in a controlled access programme with medical teams that know how to detect and treat ARIA. Patients must also start at a lower dose. The EMA said that with those measures in place, its advisory group 'concluded that Kisunla's benefits outweigh its risks in noncarriers and people with just one copy' of the gene. The European Commission has the final say on whether a new drug or vaccine is approved, but it usually adopts the EMA evaluators' recommendations. That's why drugmaker Lilly had asked the EMA group to reconsider its negative opinion on Kisunla. It argued that ARIA is usually temporary and does not cause symptoms in most cases. Alzheimer's groups were also disappointed by the initial decision. At the time, Alzheimer Europe said that while patient safety is important, strict prescribing rules and safety monitoring could help ensure dementia patients have access to the new drug while keeping it away from those at higher risk of serious side effects. Notably, the EMA and the Commission recently greenlit another Alzheimer's drug, Leqembi, that comes with similar side effects for people with the gene. In that case, the EMA group had also first refused the drug, but later recommended that it be offered to people with only one or no copies of the gene – making it the first medicine of its kind authorised in the EU. The Commission is expected to make a final decision on Kisunla in the coming months.
Fashion Network
3 days ago
- Fashion Network
Hermes heir's ex-adviser dies as $16 billion legal fight endures
The former adviser to an Hermès heir has died as a longstanding mystery over the whereabouts of company shares worth some 14 billion euros (16 billion dollars) remains unsolved. Eric Freymond worked for 24 years as a wealth manager to Hermès descendant Nicolas Puech before their relationship soured, leading to a court case in Geneva. The wealthy octogenarian Puech alleged that Freymond had played a role in the disappearance of some 6 million shares in Hermès International SCA that he had inherited. A decision by an appeals court in Geneva last year found no evidence that Freymond mismanaged Puech's fortune or that the reclusive, fifth-generation heir was duped over an extensive period during which time at least some of the stock was sold. Freymond denied all allegations of wrongdoing. Freymond's lawyer Yannis Sakkas confirmed the death, saying he was 'deeply shocked by the terrible news.' Freymond was 67. The dispute over Puech's stake in Hermes was one of the most enduring mysteries in the fallout from one of France's most high-profile corporate battles. A recent twist came from a lawsuit filed in March in Washington, DC, in which Puech was accused of failing to deliver the 16 billion dollars of Hermes shares as part of a sale agreement. His lawyer said his client was not involved in the deal. More than a decade ago Bernard Arnault, luxury goods rival and founder of conglomerate LVMH, revealed he had stealthily amassed a stake in Hermès. Descendants controlling Hermès came together and successfully fought the unwelcome advance. The fate of Puech's shares was never clarified even after Arnault's 2014 agreement with the Hermès clan to start unwinding his stake. The enigma deepened in 2023, when Puech accused Freymond of mishandling his holdings. The Hermès clan, which counts more than 100 members, is one of Europe's richest families. Should Switzerland-based Puech still hold his stake, he would be the single largest investor in the purveyor of Birkin handbags and colourful silk scarves that was founded in 1837. Freymond was born on June 21, 1958. He studied law at the Université de Genève from 1979 to 1983 before working in banking at Ferrier Lullin & Cie and Vernes Gestion, according to his website. He then created his own company, Semper Gestion in 2001, and later pursued his interest in contemporary art. In 2014, he retired from Semper Gestion and, with his wife, Caroline, opened Espace Muraille, an exhibition space in Geneva dedicated to contemporary art, the website states. According to the Geneva court document, he started working for Puech in 1998 until his mandate was canceled by the heir in 2022.
